{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T22:27:35Z","timestamp":1786660055331,"version":"build-2736575974"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41391-025-01056-6","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:34:17Z","timestamp":1765413257000},"page":"567-569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Progression of index metastases in oligometastatic hormone-sensitive prostate cancer: implications for metastases directed therapy?"],"prefix":"10.1038","volume":"29","author":[{"given":"Parth","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8878-7914","authenticated-orcid":false,"given":"Priyamvada","family":"Maitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gowtham Surya","family":"Krishnasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishika","family":"Murarka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayak","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchismita","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6011-9319","authenticated-orcid":false,"given":"Vedang","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"1056_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","volume":"87","author":"S Gillessen","year":"2025","unstructured":"Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, et al. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2025;87:157\u2013216. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.017.","journal-title":"Eur Urol"},{"key":"1056_CR2","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7.","journal-title":"Lancet"},{"key":"1056_CR3","doi-asserted-by":"publisher","first-page":"e1003998","DOI":"10.1371\/journal.pmed.1003998","volume":"19","author":"CC Parker","year":"2022","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Ali A, Amos CL, et al. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLoS Med. 2022;19:e1003998 https:\/\/doi.org\/10.1371\/journal.pmed.1003998.","journal-title":"PLoS Med"},{"key":"1056_CR4","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","volume":"404","author":"A Bossi","year":"2024","unstructured":"Bossi A, Foulon S, Maldonado X, Sargos P, MacDermott R, Kelly P, et al. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet. 2024;404:2065\u201376. https:\/\/doi.org\/10.1016\/S0140-6736(24)01865-8.","journal-title":"Lancet"},{"key":"1056_CR5","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen Y-H, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018;36:1080\u20137. https:\/\/doi.org\/10.1200\/JCO.2017.75.3657.","journal-title":"J Clin Oncol"},{"key":"1056_CR6","doi-asserted-by":"publisher","first-page":"678","DOI":"10.2967\/jnumed.119.233817","volume":"61","author":"S Fanti","year":"2020","unstructured":"Fanti S, Hadaschik B, Herrmann K. Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET\/CT Imaging: The PSMA PET Progression Criteria. J Nucl Med. 2020;61:678\u201382. https:\/\/doi.org\/10.2967\/jnumed.119.233817.","journal-title":"J Nucl Med"},{"key":"1056_CR7","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s12094-021-02764-w","volume":"24","author":"F Deodato","year":"2022","unstructured":"Deodato F, Pezzulla D, Cilla S, Ferro M, Romano C, Bonome P, et al. Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY-2 clinical trial subanalysis. Clin Transl Oncol. 2022;24:1177\u201383. https:\/\/doi.org\/10.1007\/s12094-021-02764-w.","journal-title":"Clin Transl Oncol"},{"key":"1056_CR8","doi-asserted-by":"publisher","first-page":"S147","DOI":"10.1016\/j.ijrobp.2024.07.2156","volume":"120","author":"X Qi","year":"2024","unstructured":"Qi X, Li HZ, Gao XS. Radiotherapy of the Primary Tumor and All Metastatic Lesions in Oligometastatic Prostate Cancer: 5-Year Results of Prolong Study. Int J Radiat Oncol. 2024;120:S147 https:\/\/doi.org\/10.1016\/j.ijrobp.2024.07.2156.","journal-title":"Int J Radiat Oncol"},{"key":"1056_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.eururo.2024.02.008","volume":"86","author":"NG Nickols","year":"2024","unstructured":"Nickols NG, Tsai S, Kane N, Tran S, Ghayouri L, Diaz-Perez S, et al. Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer. Eur Urol. 2024;86:190\u20133. https:\/\/doi.org\/10.1016\/j.eururo.2024.02.008.","journal-title":"Eur Urol"},{"key":"1056_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74562-3","volume":"10","author":"C Reverberi","year":"2020","unstructured":"Reverberi C, Massaro M, Osti MF, Anzellini D, Marinelli L, Montalto A, et al. Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer. Sci Rep. 2020;10:17471. https:\/\/doi.org\/10.1038\/s41598-020-74562-3.","journal-title":"Sci Rep"},{"key":"1056_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s43018-023-00692-y","volume":"5","author":"EW Warner","year":"2024","unstructured":"Warner EW, Van Der Eecken K, Murtha AJ, Kwan EM, Herberts C, Sipola J, et al. Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping. Nat Cancer. 2024;5:114\u201330. https:\/\/doi.org\/10.1038\/s43018-023-00692-y.","journal-title":"Nat Cancer"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01056-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01056-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01056-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T21:44:50Z","timestamp":1786657490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01056-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1056"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-01056-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6740073\/v1","asserted-by":"object"}]},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"24 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"We confirm that all methods were performed in accordance with the relevant guidelines and regulations. Ethical approval was taken from the Institutional Ethical Committee of Tata Memorial Hospital, Mumbai. No informed consent was taken as the Ethics Committee granted wavier.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}